Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation

New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to concerns about renal dysfunction and risk for la...

Descripción completa

Detalles Bibliográficos
Autores principales: Boerner, Brian P., Miles, Clifford D., Shivaswamy, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003765/
https://www.ncbi.nlm.nih.gov/pubmed/24817885
http://dx.doi.org/10.1155/2014/617638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003765/
https://www.ncbi.nlm.nih.gov/pubmed/24817885
http://dx.doi.org/10.1155/2014/617638

Ejemplares similares